 "At Merck, we actively pursue collaborations to turn cutting edge science into breakthrough medicines. We believe that our demonstrated track record and reputation for scientific excellence makes us a valuable partner in developing and marketing important medicines for patients around the world."
Raymond V. Gilmartin
Chairman, Chief Executive Officer and President
Merck & Co., Inc.
The cascade of knowledge flowing from biotechnology and the unraveling of the human genome - to name only two recent developments - is far too complex for any single company to handle alone. That's why Merck looks outside for insight and innovation. And that's why Merck recently has stepped up the pace of the search for such ventures.
Merck has a long history as a successful partner -- for example, among the five products that are our key drivers of growth, Fosamax and Cozaar/Hyzaar came to Merck via license agreements. We believe in 'win-win' arrangements with benefits accruing to both parties in an equitable manner. Once a licensed-in product enters Merck's pipeline, we bring the breadth of Merck's resources, talent and experience to getting the product to market and then optimizing its success in markets worldwide.
Currently, Merck's focus is to supplement our existing franchises with complementary external arrangements and to bring the best science into areas where we do not currently have products. This includes not only early-stage research collaborations leading to a compound for development, but also innovative arrangements involving products that are either established or in later stages of development.
To contact Licensing, click here.
|
